"My interests are focused on the use of monoclonal antibodies that bind to the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors for cancer therapy in combination with chemotherapy agents and radiation. The research involves investigation of the mechanisms of enhanced cytotoxicity produced by combination treatment with TRAIL death receptor antibodies and chemoradiation. Orthotopic and metastatic breast and pancreatic cancer xenograft models are being used to optimize therapeutic regimens.